Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 8Cetuximab 8Cisplatin 6Fluorouracil 5Paclitaxel 4durvalumab 3Radiotherapy 3Leucovorin 3Docetaxel 3Carboplatin 3tremelimumab 2niraparib 2avelumab 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Nivolumab 2Ipilimumab 2Bevacizumab 2zalutumumab 1yeast-CEA vaccine 1spartalizumab 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1regorafenib 1penpulimab 1paclitaxel poliglumex 1osimertinib 1necitumumab 1dostarlimab 1demplatin pegraglumer 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Squamous Cell × yeast-CEA vaccine × Clear all
NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

Phase 1/2 Terminated
4 enrolled 14 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡